You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
誠達藥業(301201.SZ)大跌超16% 未與輝瑞開展關於Paxlovid相關中間體的合作
格隆匯2月21日丨此前持續多日飆升的誠達藥業(301201.SZ)今日大跌,盤中一度跌超16%至98.01元,市值一度跌破100億元。該股此前多日大漲或受輝瑞新冠口服藥國內獲批影響。但誠達藥業20日回覆關注函稱,公司受輝瑞原料藥工廠委託定製研發的PF-07304814中間體NP1105產品,2020年、2021年1-6月份銷售收入佔公司營業收入的比例分別為0.61%和1.16%,佔比很小。2021年7月份至今,公司未接到客户該產品新的訂單。根據輝瑞2022年2月8日的公開報吿,PF-07304814的臨牀試驗已經終止。目前,公司沒有與輝瑞開展關於Paxlovid相關中間體的合作。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account